The drug maker plans to distribute 1 billion doses in the next year.
Grow your business, Not your inbox
Stay up to date and subscribe to our daily newsletter now!
3 min read
This article has been translated from our Spanish edition using AI technologies. Errors can occur due to this process.
The coronavirus vaccine will be released in the second half of 2021, according to Joaquín Duato, vice chairman of the Johnson & Johnson Executive Committee. The drug maker plans to distribute 1 billion doses at a cost of less than $ 10.
The race for the long-awaited vaccine against COVID-19 is getting closer. Pharmaceutical Janssen, part of the Johnson & Johnson group, promises that its vaccine will be available in the second half of 2021. And the best part is the price as it would cost less than $ 10 which is around 200 Mexican pesos.
Joaquín Duato, Vice President of the Executive Committee of the American multinational, announced the good news during a conference at the health sector meeting organized by IESE Business School in collaboration with consultancy McKinsey & Company.
I was honored to attend @IESEBschool's annual Healthcare 2020 industry event today, which this year focused on fighting # COVID19. I discussed #JNJ's efforts to develop a vaccine candidate and the many valuable lessons we have learned along the way. pic.twitter.com/gYscqf04tV
– Joaquin Duato (@joaquinduato) November 19, 2020
The study by the pharmaceutical company Janssen, approved yesterday by the Spanish Agency for Medicines and Health Products, guarantees the vaccine "sometime in the first or second half of 2021".
The executive director of Johnson & Johnson said the pharmaceutical company has a plan to deliver 1,000 million in 2021. This will be achieved through collaborative networks with governments and organizations like COVAX, a project that will be allocated 500 million doses. its production for the lower income countries.
"There will be good news for the next six months. We can see these potent vaccines become available to the public," Duato said at the same event. He added that the vaccine they are working on will also guarantee "the quality and safety standards" announced by other companies in the industry.
The multinational affirms that the cost of the vaccine is not for profit, but for the common good. "We will try to ensure access to the vaccine in all areas. The price will not be more than $ 10 per vaccine," said the manager.
This week the American pharmaceutical companies Pfizer and Moderna published the clinical results of the phase 3 of their respective vaccines. Both were nearly 95% effective, which is great news for the rest of the labs focused on the same protein.
Regarding the coronavirus vaccine race, the executive said, "It's not a competitive situation, it's a social problem and a global crisis where we need multiple vaccines, not just one because we have to vaccinate millions of people" .